Post-earnings recap
Reported
Wed, Aug 4, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
Protagonist Therapeutics reported a wider-than-expected loss per share, which contributed to a slight decline in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's near-term performance. The stock reaction reflects uncertainty in the market regarding future developments.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.69 | N/A | -11.29% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook without providing specific guidance. They emphasized the importance of ongoing clinical trials.
Management did not provide specific guidance for future quarters.
The focus remains on advancing clinical programs.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—